# REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

> **NCT07675824** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 271 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma (POAG)
- Ocular Hypertension (OHT)

## Interventions

- **DRUG:** REGN22530

## Key facts

- **NCT ID:** NCT07675824
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-08
- **Primary completion:** 2029-09-14
- **Final completion:** 2029-12-06
- **Target enrollment:** 271 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675824, "REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07675824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*